Tyrosine Kinases / Adaptors
Phospho-Her3/ErbB3 (Tyr1289) Blocking Peptide
|
イイネ!(0)
|
|
| CSTコード |
包装 |
希望納入価格 (円) |
国内在庫  |
ご登録代理店情報  カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #1180S | 100 μg | 16,000 | |
|
HER3/ErbB3抗体製品一覧
| 使用目的 | |
| Phospho-Her3/ErbB3 (Tyr1289) (21D3) Rabbit mAb (#4791) の反応をブロックし、抗体の反応特異性を確認するために使用 |
IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human lung carcinoma, using Phospho-HER3/ErbB3 (Tyr1289) (21D3) Rabbit mAb #4791 (left) or the same antibody preincubated with Phospho-HER3/ErbB3 (Tyr1289) (21D3) Blocking Peptide (right).
HER3/ErbB3 is a member of the ErbB receptor protein tyrosine kinase family, but lacks tyrosine kinase activity. Tyrosine phosphorylation of ErbB3 depends on its association with other ErbB tyrosine kinases. Upon ligand binding, heterodimers form between ErbB3 and other ErbB proteins and ErbB3 is phosphorylated on tyrosine residues by the activated ErbB kinase (1,2). There are at least 9 potential tyrosine phosphorylation sites in the carboxy-terminal tail of ErbB3. These sites serve as consensus binding sites for signal transducing proteins, including Src family members, Grb2, and the p85 subunit of PI3 kinase, which mediate ErbB downstream signaling (3). Both Tyr1222 and Tyr1289 of ErbB3 reside within a YXXM motif and participate in signaling to PI3 kinase (4).ErbB3 is highly expressed in many cancer cells (5) and activation of the ErbB3/PI3K pathway is correlated with malignant phenotypes of adenocarcinomas (6). In tumor development, ErbB3 may function as an oncogenic unit together with other ErbB members (e.g. ErbB2 requires ErbB3 to drive breast tumor cell proliferation) (7). Thus, inhibiting interaction between ErbB3 and ErbB tyrosine kinases has become a novel strategy for anti-tumor therapy.
-
Yarden, Y. and Sliwkowski, M.X. (2001) Nature Rev. Mol. Cell. Biol. 2, 127-137.
-
Guy, P.M. et al. (1994) Proc. Natl. Acad. Sci. USA 91, 8132-8136.
-
Songyang, Z. et al. (1993) Cell 72, 767-778.
-
Kim, H.H. et al. (1994) J. Biol. Chem. 269, 24747-24755.
-
Sithanandam, G. et al. (2003) Carcinogenesis 24, 1581-1592.
-
Kobayashi, M. et al. (2003) Oncogene 22, 1294-1301.
-
Holbro, T. et al. (2003) Proc. Natl. Acad. Sci. USA 100, 8933-8938.